摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

dicyclohexylamine 1-(((1(R)-(3-(2-(7-chloro-2-quinolidyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropanylacetate | 169954-94-3

中文名称
——
中文别名
——
英文名称
dicyclohexylamine 1-(((1(R)-(3-(2-(7-chloro-2-quinolidyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropanylacetate
英文别名
2-[1-[[(1R)-1-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid;N-cyclohexylcyclohexanamine
dicyclohexylamine 1-(((1(R)-(3-(2-(7-chloro-2-quinolidyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropanylacetate化学式
CAS
169954-94-3
化学式
C12H23N*C35H36ClNO3S
mdl
——
分子量
767.516
InChiKey
ZLOLVGQQYDQBMP-RYWNGCACSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    12.19
  • 重原子数:
    54
  • 可旋转键数:
    14
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.49
  • 拓扑面积:
    108
  • 氢给体数:
    3
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • Process for the Preparation of Montelukast and its Salts
    申请人:Chava Satyanarayana
    公开号:US20090143590A1
    公开(公告)日:2009-06-04
    The present invention relates to an improved process for the preparation of 1-[[[(1R)-1-[3[(1E)-2-(7chloro-2-quinolinyl) ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl) phenyl] propyl] thio] methyl] cyclopropaneacetic acid (Formula-1) and its salts using Methyl 2-[(3S)-[3-[(2E)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoate (Formula-2)
    该发明涉及一种改进的制备1-[[[(1R)-1-[3[(1E)-2-(7氯-2-喹啉基) 乙烯基] 苯基]-3-[2-(1-羟基-1-甲基乙基) 苯基] 丙基] 硫] 甲基] 环丙酸(Formula-1)及其盐的方法,使用甲基2-[(3S)-[3-[(2E)-(7-氯喹啉-2-基) 乙烯基] 苯基]-3-卤代丙基] 苯甲酸酯(Formula-2)。
  • [EN] METHOD FOR THE PREPARATION OF MONTELUKAST ACID IN IONIC LIQUID MEDIUM<br/>[FR] PROCÉDÉ DE FABRICATION D'ACIDE MONTÉLUKAST DANS UN MILIEU LIQUIDE IONIQUE
    申请人:HANMI PHARM IND CO LTD
    公开号:WO2009048236A1
    公开(公告)日:2009-04-16
    The present invention relates to a method for preparing Montelukast acid or its sodium salt by reacting a thiol compound with a Montelukast intermediate in the presence of a base in a medium comprising an ionic liquid compound. In accordance with the inventive method, highly pure Montelukast acid or its sodium salt, which is advantageously used as a raw material in the preparation of Montelukast, a leukotriene antagonist, can be easily prepared in a high yield.
    本发明涉及一种通过在含有离子液体化合物的介质中,在碱的存在下,将硫醇化合物与Montelukast中间体反应,制备Montelukast酸或其钠盐的方法。根据这一创新方法,可以轻松高产地制备高纯度的Montelukast酸或其钠盐,这在制备Montelukast,一种白三烯拮抗剂的原料中具有优势。
  • PROCESS FOR OBTAINING MONTELUKAST
    申请人:Perez Andres Juan Antonio
    公开号:US20080194825A1
    公开(公告)日:2008-08-14
    The present invention refers to a process for the synthesis of (1-1-(R)-(E)-3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propylsulfanylmethyl}-cyclopropyl)-acetic acid or its salts, comprising the reaction between 7-Chloro-2-vinyl-quinoline and a compound of formula (I) wherein X is a halogen atom or a group of formula —OSO 2 R, wherein R is selected from the group consisting of CF 3 , tolyl, methyl and F; in the presence of a palladium based catalyst. The invention is also directed to intermediates compounds of the process.
    本发明涉及一种合成(1-1-(R)-(E)-3-[2-(7-氯喹啉-2-基)-乙烯基]-苯基}-3-[2-(1-羟基-1-甲基-乙基)-苯基]-丙基硫醇甲基}-环丙基)-乙酸或其盐的过程,包括在钯基催化剂存在下,7-氯-2-乙烯基喹啉与式(I)化合物之间的反应,其中X是卤素原子或式—OSO2R的基团,其中R选自由CF3、甲苯、甲基和F组成的群;本发明还涉及该过程的中间体化合物。
  • Purification of montelukast using simulated moving bed
    申请人:Mandal Arun Kanti
    公开号:US20120142931A1
    公开(公告)日:2012-06-07
    This invention concerns generally with a process for purifying crude pharmaceutical compositions, wherein the crude pharmaceutical composition comprises a sodium salt of Montelukast and more particularly relates to a process for the production of pharmaceutically pure preparations of Montelukast sodium using simulated moving bed technology, without requiring an intermediate acid formation step to separate isomers and to remove impurities.
    本发明通常涉及一种用于纯化原始药物组合物的过程,其中原始药物组合物包括蒙特卢卡斯特钠盐,更具体地涉及一种使用模拟移动床技术生产药学纯蒙特卢卡斯特钠制剂的过程,无需进行中间酸形成步骤来分离异构体并去除杂质。
  • CRYSTALLINE SALT OF MONTELUKAST
    申请人:Huguet Clotet Joan
    公开号:US20090111849A1
    公开(公告)日:2009-04-30
    Cyclopropylamine salt of montelukast in crystalline form and its use for the preparation of highly pure amorphous montelukast sodium.
    环丙胺盐酸蒙特卢卡斯特的晶态形式及其用于制备高纯度无定形蒙特卢卡斯特钠的用途。
查看更多